AR127714A1 - UNIDADES DE UNIÓN MULTIESPECÍFICAS QUE COMPRENDEN LOS DOMINIOS DE UNIÓN A PD-1 Y TGF-bRII - Google Patents

UNIDADES DE UNIÓN MULTIESPECÍFICAS QUE COMPRENDEN LOS DOMINIOS DE UNIÓN A PD-1 Y TGF-bRII

Info

Publication number
AR127714A1
AR127714A1 ARP220103179A ARP220103179A AR127714A1 AR 127714 A1 AR127714 A1 AR 127714A1 AR P220103179 A ARP220103179 A AR P220103179A AR P220103179 A ARP220103179 A AR P220103179A AR 127714 A1 AR127714 A1 AR 127714A1
Authority
AR
Argentina
Prior art keywords
brii
tgf
binding unit
binding domain
multispecific
Prior art date
Application number
ARP220103179A
Other languages
English (en)
Spanish (es)
Inventor
Cecilia Anna Wilhelmina Geuijen
Patrick Mayes
Shaun M Stewart
Liang-Chuan Wang
Original Assignee
Merus Nv
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv, Incyte Corp filed Critical Merus Nv
Publication of AR127714A1 publication Critical patent/AR127714A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ARP220103179A 2021-11-19 2022-11-18 UNIDADES DE UNIÓN MULTIESPECÍFICAS QUE COMPRENDEN LOS DOMINIOS DE UNIÓN A PD-1 Y TGF-bRII AR127714A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL2029844 2021-11-19

Publications (1)

Publication Number Publication Date
AR127714A1 true AR127714A1 (es) 2024-02-21

Family

ID=80625531

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220103179A AR127714A1 (es) 2021-11-19 2022-11-18 UNIDADES DE UNIÓN MULTIESPECÍFICAS QUE COMPRENDEN LOS DOMINIOS DE UNIÓN A PD-1 Y TGF-bRII

Country Status (18)

Country Link
US (1) US20230159645A1 (https=)
EP (1) EP4433505A1 (https=)
JP (1) JP2024542879A (https=)
KR (1) KR20240101664A9 (https=)
CN (2) CN118265725A (https=)
AR (1) AR127714A1 (https=)
AU (1) AU2022389596A1 (https=)
CA (1) CA3231649A1 (https=)
CL (1) CL2024001410A1 (https=)
CO (1) CO2024006325A2 (https=)
CR (1) CR20240201A (https=)
EC (1) ECSP24039278A (https=)
IL (1) IL312214A (https=)
MX (1) MX2024006018A (https=)
PE (1) PE20241477A1 (https=)
TW (1) TW202328180A (https=)
UY (1) UY40028A (https=)
WO (1) WO2023089083A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240343805A1 (en) * 2023-04-14 2024-10-17 Incyte Corporation USE OF AN ANTI-TGFßR2/PD-1 BISPECIFIC ANTIBODY

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
WO2018129331A1 (en) * 2017-01-07 2018-07-12 Merck Patent Gmbh Dosing regimens and dosage forms for targeted tgf-b inhibition
MX2020000055A (es) * 2017-07-06 2020-08-06 Merus Nv Anticuerpos biespecificos antiproteina 1 de muerte celular programada (pd-1) -anti inmunoglobulina de celulas t y dominio de mucina que contiene -3 (tim-3).
AU2018296067B2 (en) * 2017-07-06 2021-06-10 Merus B.V. Binding molecules that modulate a biological activity expressed by a cell
CN116199780A (zh) * 2019-12-24 2023-06-02 美勒斯公司 TGF-β-RII结合蛋白质
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
US20220144956A1 (en) * 2020-11-06 2022-05-12 Xencor, Inc. HETERODIMERIC ANTIBODIES THAT BIND TGFbetaRII

Also Published As

Publication number Publication date
CO2024006325A2 (es) 2024-06-27
CL2024001410A1 (es) 2024-08-30
US20230159645A1 (en) 2023-05-25
WO2023089083A1 (en) 2023-05-25
UY40028A (es) 2023-05-31
AU2022389596A1 (en) 2024-05-30
CN118265725A (zh) 2024-06-28
PE20241477A1 (es) 2024-07-17
ECSP24039278A (es) 2024-07-31
KR20240101664A (ko) 2024-07-02
JP2024542879A (ja) 2024-11-18
MX2024006018A (es) 2024-07-29
EP4433505A1 (en) 2024-09-25
IL312214A (en) 2024-06-01
CN119613560A (zh) 2025-03-14
TW202328180A (zh) 2023-07-16
CR20240201A (es) 2024-07-15
CA3231649A1 (en) 2023-05-25
KR20240101664A9 (ko) 2025-12-10

Similar Documents

Publication Publication Date Title
DOP2019000266A (es) Inhibidores de pd-1/pd-l1
MX2019006622A (es) Composicion farmaceutica para la prevencion o tratamiento de cancer, que comprende polimorfo cristalino de hexoxido de tetraarsenico.
CL2019000270A1 (es) Composición de cannabis.
MX388460B (es) Composiciones de yodo.
CL2012003110A1 (es) Compuestos derivados de n-[(2-oxo-1,2-dihidro-3-piridinil)metil]-1h-indol-4-carboxamida, inhibidores de ezh2; composicion farmaceutica que los contiene; utiles en el tratamiento del cancer seleccionado del grupo que consiste de cerebro (gliomas) glioblastomas, leucemias y linfomas, y trastornos mediados por la inhibicion del ezh2.
MX2020004858A (es) Compuestos moduladores de sting y metodos de elaboracion y uso.
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
UY34382A (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
CO6531463A2 (es) Combinaciones de un inhibidor de pi3k y un inhibidor de mek
DOP2023000074A (es) Compuestos fosfolípidos y usos de estos
BR112022027101A2 (pt) Anticorpos multiespecíficos que se ligam a bcma
MX2024008886A (es) Sulfonamida sustituida con trifluorometilo como inhibidor selectivo de bcl-2.
CO2023001953A2 (es) Compuestos fosfolípidos y usos de los mismos
DOP2014000074A (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
CL2011002206A1 (es) Compuestos derivados de benzofurano sustituidos, moduladores del señalador igf1 o activador de la proteina quinasa b; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades del snc, tales como alzheimer, entre otras.
BR112016026560A2 (pt) Método para tratar uma complicação de uma doença hepática crônica, método para tratar hipertensão portal, método para inibir uma cascata de sinalização de tnf-a e de a-fas; composição farmacêutica, kit, método de tratamento, método para tratar uma afecção
CO2020015377A2 (es) Moduladores de la expresión de apol1
ECSP23076906A (es) Composiciones y métodos para inhibir cetohexoquinasa (khk)
UY39958A (es) Compuestos de imidazopiridazina inhibidores de il-17
AR127714A1 (es) UNIDADES DE UNIÓN MULTIESPECÍFICAS QUE COMPRENDEN LOS DOMINIOS DE UNIÓN A PD-1 Y TGF-bRII
AR095594A1 (es) Métodos para tratar infecciones en pacientes con sobrepeso y obesos usando antibióticos
MX2024010977A (es) Composiciones que comprenden aticaprant
CO2021007006A2 (es) Moduladores de la expresión de irf5
MX2021011334A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX2019002259A (es) Inhibicion de la actividad de la olig2.